ALLMedicine™ Hemophilia B Center

Apr 8th, 2021 - Hemophilia B is a rare congenital blood disorder characterized by factor IX deficiency. Clinical profiles of hemophilia B range from mild to severe forms of the disease. The objective of this study was to characterize the economic burden associate...

Mar 24th, 2021 - Genetic characteristics and genetic carrier diagnosis in Japanese hemophilia female carriers have not been evaluated. To provide genetic information on Japanese hemophilia female carriers and demonstrate the advantages of genetic testing in carrie...

Mar 21st, 2021 - Hemophilia B is a rare congenital bleeding disorder that has a significant negative impact on patients' functionality and health-related quality of life. The standard of care for severe hemophilia B in the United States is prophylactic factor IX r...

Mar 18th, 2021 - Sustained expression of therapeutic factor IX (FIX) levels has been achieved after adeno-associated viral (AAV) vector-based gene therapy in patients with hemophilia B. Nevertheless, patients are still at risk of vector dose-limiting toxicity, par...

Mar 4th, 2021 - In the rare co-occurrence of childhood cancer and severe hemophilia, hemostatic management is of paramount therapeutic importance. We present the case of an 11-month-old boy with severe congenital hemophilia B, who was diagnosed with metastatic hi...

Dec 4th, 2020 - Haemophilia B (HB) is less well studied than haemophilia A (HA); despite similarities between the two inherited bleeding disorders, important differences remain that require further research.

Nov 7th, 2020 - Hemophilia is the most common X‐linked bleeding disorder, affecting over 1 million individuals throughout the world. Patients are subclassified into mild, moderate and severe disease based on per cent factor activity level.

Oct 13th, 2020 - Hemophilia is an inherited disease that requires a different approach in order to evaluate, monitor and treat patients. Despite the great advances in therapeutic agents that have emerged, reports on the impact of monitoring outcomes on treatment d...

Aug 2nd, 2020 - This new edition of the World Federation of Hemophilia (WFH) guidelines for the management of hemophilia comes at an exciting time in the evolution of the diagnosis and treatment of this condition. Since the publication of the second edition in 20...

Jan 23rd, 2017 - Prior to the availability of clotting factor concentrates, the natural history of arthropathy in severe haemophilia was well described, with recurrent bleeds into joints leading to progressive joint damage and ultimate destruction with associa...

Apr 8th, 2021 - Hemophilia B is a rare congenital blood disorder characterized by factor IX deficiency. Clinical profiles of hemophilia B range from mild to severe forms of the disease. The objective of this study was to characterize the economic burden associate...

Mar 24th, 2021 - Genetic characteristics and genetic carrier diagnosis in Japanese hemophilia female carriers have not been evaluated. To provide genetic information on Japanese hemophilia female carriers and demonstrate the advantages of genetic testing in carrie...

Mar 21st, 2021 - Hemophilia B is a rare congenital bleeding disorder that has a significant negative impact on patients' functionality and health-related quality of life. The standard of care for severe hemophilia B in the United States is prophylactic factor IX r...

Mar 18th, 2021 - Sustained expression of therapeutic factor IX (FIX) levels has been achieved after adeno-associated viral (AAV) vector-based gene therapy in patients with hemophilia B. Nevertheless, patients are still at risk of vector dose-limiting toxicity, par...

Mar 17th, 2021 - BeneFIX®, Coagulation Factor IX (Recombinant), is a human blood coagulation factor indicated in adults and children with hemophilia B (congenital factor IX deficiency or Christmas disease) for: on-demand treatment and control of bleeding episodes ...

Dec 17th, 2020 - NEW YORK (Reuters Health) - An investigational gene therapy for hemophilia B substantially increased production of the blood-clotting protein factor IX and reduced the number of bleeding episodes and need for prophylactic therapy in a phase-3 tria...

Dec 4th, 2020 - Haemophilia B (HB) is less well studied than haemophilia A (HA); despite similarities between the two inherited bleeding disorders, important differences remain that require further research.

Nov 7th, 2020 - Hemophilia is the most common X‐linked bleeding disorder, affecting over 1 million individuals throughout the world. Patients are subclassified into mild, moderate and severe disease based on per cent factor activity level.

Oct 21st, 2020 - Hemophilia A is an inherited deficiency of FVIII and an X-linked recessive disorder. Hemophilia B, another recessive disorder, is characterized by a deficiency in factor IX. Hemophilia C is an autosomal recessive disorder in which patients are def...

Oct 13th, 2020 - Hemophilia is an inherited disease that requires a different approach in order to evaluate, monitor and treat patients. Despite the great advances in therapeutic agents that have emerged, reports on the impact of monitoring outcomes on treatment d...